ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of the “at-the market” equity of its providing plan.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering system under which Acasti might issue and market from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January 27, 2021, Acasti granted an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being offered at prevailing market prices averaging US$1.0747 a share. No securities had been sold in the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with extra freedom in its continuous review process to enjoy as well as evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of efficacy as well as safety in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for people with serious HTG.
Forward Looking Statements – ACST Stock
Statements in this press release that aren’t statements of historical or current fact constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking statements include known and unknown risks, uncertainties, along with other unknown factors that may result in the particular results of Acasti to be materially different from historical outcomes and even as a result of any later outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, readers are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward looking statements, which speak only as of the day of this press release. Forward-looking claims in this press release include, but aren’t restricted to, statements or info about Acasti’s strategy, future operations and the review of its of strategic alternatives.
The forward-looking claims found in this specific press release are expressly qualified in their entirety by this alerting statement, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and on the investor aisle of Acasti’s website at www.acastipharma.com. All forward looking statements in that press release are available as of the particular date of this press release.
ACST Stock – Acasti doesn’t undertake to upgrade any such forward looking statements whether as a consequence of info that is new , future events or perhaps otherwise, except as called for by law. The forward-looking statements contained herein are also subject typically to assumptions and risks as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the use